Summary
- IN8bio has filed proposed terms for its U.S. IPO.
- The firm is developing treatments for brain and blood cancer.
- INAB is still a very early stage firm with no preliminary data on its lead programs until 2021, so I'll watch the IPO from the sidelines.
- Looking for more investing ideas like this one? Get them exclusively at IPO Edge. Get started today »
Quick Take
IN8bio (INAB) intends to raise $75 million from the sale of its common stock in an IPO, according to an amended registration statement.
The company is developing treatments for brain cancer and blood cancer.
INAB has much of its pipeline still in a preclinical stage of development, so the IPO may be more suited to institutional investors with long hold time horizons.
Company & Technology
New York, New York-based IN8bio was founded to advance a pipeline of treatment options for glioblastoma [GBM] and acute leukemia using ‘allogeneic, autologous and genetically modified gamma-delta T cells.’
The advantage of employing gamma-delta T cells is that they kill cancer cells 'while possessing a tumor recognition mechanism that protects healthy tissue.'
Management is headed by co-founder, president, CEO and CFO William Ho, who was previously founder and Managing Partner at AlephPoint Capital, a healthcare venture capital firm.
Below is a brief overview video of glioblastoma:
